Emcure Pharmaceuticals Ltd

Emcure Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Emcure Pharmaceuticals Ltd

₹ 1,657 -0.03%
13 May - close price
emcure.com BSE: 544210 NSE: EMCURE
About

Incorporated in 1981, Emcure Pharmaceuticals
Ltd manufactures and markets pharmaceutical products globally[1]

Key Points

Business Overview:[1][2]
EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.

Website BSE NSE
  • Market Cap ₹ 31,426 Cr.
  • Current Price ₹ 1,657
  • High / Low ₹ 1,830 / 1,029
  • Stock P/E 33.2
  • Book Value ₹ 261
  • Dividend Yield 0.18 %
  • ROCE 24.0 %
  • ROE 20.1 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,556 1,663 1,668 1,771 1,815 2,002 1,963 2,116 2,101 2,270 2,363 2,470
1,261 1,334 1,374 1,460 1,479 1,621 1,608 1,714 1,684 1,794 1,871 1,990
Operating Profit 296 329 294 311 336 381 355 402 417 475 493 480
OPM % 19% 20% 18% 18% 19% 19% 18% 19% 20% 21% 21% 19%
15 -2 22 12 23 36 4 -6 0 3 -36 14
Interest 52 59 61 65 59 46 32 39 27 33 38 46
Depreciation 67 70 84 91 94 97 97 97 99 105 105 106
Profit before tax 191 198 171 167 207 273 230 261 291 341 314 341
Tax % 26% 26% 30% 27% 26% 26% 32% 24% 26% 26% 26% 29%
141 146 120 121 153 202 156 197 215 251 231 244
EPS in Rs 7.21 7.69 6.27 6.36 7.95 10.29 8.11 9.97 10.92 12.84 12.16 12.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
4,717 5,049 5,033 5,855 5,986 6,658 7,896 9,204
3,968 4,340 3,817 4,525 4,804 5,429 6,427 7,339
Operating Profit 749 708 1,216 1,330 1,182 1,230 1,469 1,865
OPM % 16% 14% 24% 23% 20% 18% 19% 20%
72 -25 -159 63 39 47 62 -19
Interest 223 257 155 176 214 237 176 144
Depreciation 267 321 250 245 260 312 384 415
Profit before tax 331 105 652 973 747 727 971 1,287
Tax % 37% 4% 36% 28% 25% 27% 27% 27%
209 101 419 703 562 528 707 941
EPS in Rs 10.79 4.62 23.15 36.62 29.42 27.50 35.96 48.76
Dividend Payout % 32% 54% 4% 8% 7% 7% 8% 0%
Compounded Sales Growth
10 Years: %
5 Years: 13%
3 Years: 15%
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: 18%
3 Years: 21%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 60%
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 19%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 181 181 181 181 181 181 189 190
Reserves 1,654 1,731 2,092 1,807 2,320 2,771 4,257 4,760
2,128 2,327 2,310 2,217 2,334 2,335 1,023 1,558
1,613 1,721 2,184 1,816 1,798 2,422 2,653 3,104
Total Liabilities 5,577 5,960 6,768 6,021 6,634 7,709 8,122 9,612
2,247 2,382 2,188 2,044 2,147 3,125 3,197 3,420
CWIP 581 485 302 320 411 159 177 172
Investments 0 0 0 25 25 318 95 20
2,749 3,093 4,278 3,632 4,050 4,108 4,652 6,001
Total Assets 5,577 5,960 6,768 6,021 6,634 7,709 8,122 9,612

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
444 500 704 768 747 1,097 852 944
-409 -168 -256 -574 -468 -715 -96 -1,193
-735 -301 -189 -152 -145 -164 -814 343
Net Cash Flow -700 32 259 42 134 219 -58 94
Free Cash Flow 39 362 571 349 345 801 475 400
CFO/OP 77% 84% 74% 81% 80% 107% 75% 70%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 75 83 107 82 101 102 93 102
Inventory Days 234 211 293 237 223 225 224 237
Days Payable 142 133 188 184 175 193 172 175
Cash Conversion Cycle 167 161 212 135 148 134 145 163
Working Capital Days -15 -28 -16 9 22 28 76 62
ROCE % 11% 22% 26% 21% 19% 21% 24%

Insights

In beta
Mar 2016 Mar 2019 Mar 2020 Mar 2023 Mar 2024 Mar 2025
Number of Manufacturing Facilities
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Field Force Representatives
Number
R&D Spend as % of Revenue
%
Number of Granted Patents
Number
Number of Large Brand Families (>50Cr Revenue in India)
Number
Product Launches - Global
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently
Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
78.08% 77.94% 77.92% 77.92% 77.88% 77.87% 77.87%
2.91% 3.05% 3.06% 2.86% 3.29% 3.59% 3.35%
3.96% 3.87% 3.44% 2.84% 4.36% 6.10% 6.10%
15.05% 15.15% 15.58% 16.39% 14.46% 12.43% 12.69%
No. of Shareholders 1,52,9141,43,4491,39,6711,33,5491,26,1691,18,8631,22,189

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls